{
    "2018-08-24": [
        [
            {
                "time": "2018-08-24",
                "original_text": "A股共发生43宗大宗交易成交7.78亿元（8月24日）",
                "features": {
                    "keywords": [
                        "A股",
                        "大宗交易",
                        "成交额"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "金融"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-08-24",
                "original_text": "贝达药业今日大宗交易成交20万股，成交价42.45元折价0.0%",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "大宗交易",
                        "成交价",
                        "折价率"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-08-24",
                "original_text": "[增持评级] 贝达药业(300558)半年报点评：降价冲击逐渐减弱 期待新产品贡献新增业绩增量",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "半年报",
                        "降价冲击",
                        "新产品",
                        "业绩增量"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-08-24",
                "original_text": "[买入评级] 贝达药业(300558)中报点评：业绩符合预期 高研发投入持续推进 静待利润新品种上市",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "中报",
                        "业绩",
                        "高研发投入",
                        "新品种上市"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-08-24",
                "original_text": "[推荐评级] 贝达药业(300558)半年报点评：凯美纳继续放量 降价影响逐渐减弱 研发投入持续增加",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "半年报",
                        "凯美纳",
                        "降价影响",
                        "研发投入"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-08-24",
                "original_text": "[中性评级] 贝达药业(300558)中报点评：2018年1H业绩低于预期 期待下半年ALK靶向新药进展",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "中报",
                        "业绩",
                        "ALK靶向新药"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}